Comparison of early,middle and long-term therapeutic efficacies of different doses of calcitriol combined with Wuqinxi on postmenopausal osteoporosis patients
Objective To investigate the early,middle and long-term therapeutic efficacies of different doses of calcitriol combined with Wuqinxi on postmenopausal osteoporosis patients.Methods A total of 106 patients with postmenopausal osteoporosis admitted to Hongqi Hospital Affiliated to Mudanjiang Medical University from July 2022 to January 2023 were selected as the research subjects.The patients were divided into the control group(n=53)and the observation group(n=53)according to the random number table method.The control group was treated with low dose of calcitriol combined with Wuqinxi,while the observation group was treated with high dose of calcitriol combined with Wuqinxi.At 3,6,and 12 months of treatment,the early,medium,and long-term efficacy of the two therapies was compared in terms of lumbar spine L1-L4 bone density,alkaline phosphatase(ALP)levels,psychological and pain scores.Results At 3 and 6 months of treatment,there was no statistically significant difference in lumbar spine L1-L4 bone density,ALP level and pain score between the two groups(P＞0.05).At 12 months of treatment,patients in the observation group had higher lumbar spine L1-L4 bone density and pain scores and lower ALP levels than the control group,with statistically significant differences(P＜0.05).At 3,6 and 12 months of treatment,the psychological scores of patients in the two groups were compared,and the differences were not statistically significant(P＞0.05).Conclusion For postmenopausal osteoporosis patients,with different doses of calcitriol combined with Wuqinxi treatment,there is no statistically significant difference in the early and middle therapeutic efficacies.However,in terms of long-term therapeutic efficacy,high dose of calcitriol combined with Wuqinxi is more ideal.
万方数据
维普
